BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32158687)

  • 1. Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway.
    Liu J; Zheng Y; Gao Y; Quan Z; Qiao B; Li L; Li T; Duan L; Yang J; Luo C; Wu X
    Front Oncol; 2020; 10():75. PubMed ID: 32158687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PLCε knockdown overcomes drug resistance to androgen receptor antagonist in castration-resistant prostate cancer by suppressing the wnt3a/β-catenin pathway.
    Li L; Du Z; Gao Y; Tang Y; Fan Y; Sun W; Li T; Liu N; Yuan M; Fan J; Niu L; Yan J; Duan L; Wu X; Luo C
    J Cell Physiol; 2019 Sep; 234(9):15472-15486. PubMed ID: 30684266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway.
    Frontiers Editorial Office
    Front Oncol; 2021; 11():707608. PubMed ID: 34136414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1.
    Gao Y; Li L; Li T; Ma L; Yuan M; Sun W; Cheng HL; Niu L; Du Z; Quan Z; Fan Y; Fan J; Luo C; Wu X
    Int J Oncol; 2019 Jun; 54(6):2054-2068. PubMed ID: 31081050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin mitigates PLCε gene expression and modulates the Notch1/Hes and androgen receptor signaling pathways in castration-resistant prostate cancer xenograft models.
    Li Q; Xu K; Tian J; Lu Z; Pu J
    Oncol Lett; 2021 Oct; 22(4):715. PubMed ID: 34429755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
    Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
    Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study on the influence of metformin on castration-resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCε gene-mediated Notch1/Hes and androgen receptor signaling pathway.
    Yang Y; Wu XH
    Eur Rev Med Pharmacol Sci; 2017 Apr; 21(8):1918-1923. PubMed ID: 28485785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
    Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
    Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.
    Shiota M; Fujimoto N; Imada K; Yokomizo A; Itsumi M; Takeuchi A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26857528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid hormone synthetic pathways in prostate cancer.
    Mostaghel EA
    Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
    Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
    Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
    Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
    Shafran JS; Andrieu GP; Györffy B; Denis GV
    Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipase C (PLC)ε Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line.
    Yuan M; Gao Y; Li L; Sun W; Cheng H; Li T; Niu L; Du Z; Quan Z; Luo C; Wu X
    Med Sci Monit; 2019 Jun; 25():4438-4449. PubMed ID: 31201297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.